Advertisement
NKGN फॉरेक्स के समाचार
NKGen Biotech Receives Clearance For SNK01 NK Cell Therapy Clinical Trial From Health Canada
Biotechnology company NKGen Biotech Inc. (NKGN) announced Wednesday that it has received a No Objection Letter from Health Canada for its Clinical Trial Application for a Phase 1/2a study to evaluate the safety, tolerability, and exploratory efficacy of SNK01 natural killer cell therapy for the treatment of patients with moderate Alzheimer's Disease.
RTTNews
|
617 दिनों पहले